Phase 2 Study of TAT4 Gel for Reduction of Nasolabial Folds

Topokine Therapeutics, Inc.111 enrolled

Overview

This is a Phase 2, randomized, double-blind, placebo-controlled study of TAT4 Gel for the reduction of moderate to severe nasolabial folds.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

111

Conditions

Nasolabial Folds

Interventions

TAT4 GelDRUG

Matching placeboDRUG

Eligibility

Sex: ALLMin age: 35 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Moderate to severe, bilateral nasolabial folds * Must understand and provide informed consent Exclusion Criteria: * Pregnant or lactating women * History of skin hypersensitivity of atopic dermatitis * Any illness of disease that, in the investigator's opinion, would make trial participation inadvisable

Locations (1)

Topokine Research Site

Boston, Massachusetts, United States

RECRUITING

Outcomes

Primary Outcomes

Nasolabial Fold Severity Scale (Clinician-Reported)

Time frame: Day 91

Central Contacts

Michael S Singer, MD, PhD

CONTACT

volunteers@topokine.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.